AD Neurogenesis and Neuroregeneration Companies

Migration, Crosslink

📖

AD Neurogenesis and Neuroregeneration Companies

active

wiki page Created: 2026-04-02T07:20:06 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-ad-neurogenesis-companies

📖 Wiki Page

company1295 wordssynced 2026-04-02

Alzheimer's Disease Neurogenesis and Neuroregeneration Companies

Overview

flowchart TD companies_ad_neurogenesis_comp["AD Neurogenesis and Neuroregeneration Companies"] style companies_ad_neurogenesis_comp fill:#4fc3f7,stroke:#333,color:#000 companies_ad_neuroge_0["Key Therapeutic Approaches"] companies_ad_neurogenesis_comp -->|"includes"| companies_ad_neuroge_0 style companies_ad_neuroge_0 fill:#81c784,stroke:#333,color:#000 companies_ad_neuroge_1["Stem Cell-Derived Neuron Therapies"] companies_ad_neurogenesis_comp -->|"includes"| companies_ad_neuroge_1 style companies_ad_neuroge_1 fill:#ef5350,stroke:#333,color:#000 companies_ad_neuroge_2["SanBio Co., Ltd."] companies_ad_neurogenesis_comp -->|"includes"| companies_ad_neuroge_2 style companies_ad_neuroge_2 fill:#ffd54f,stroke:#333,color:#000 companies_ad_neuroge_3["Cynata Therapeutics"] companies_ad_neurogenesis_comp -->|"includes"| companies_ad_neuroge_3 style companies_ad_neuroge_3 fill:#ce93d8,stroke:#333,color:#000 companies_ad_neuroge_4["BlueRock Therapeutics"] companies_ad_neurogenesis_comp -->|"includes"| companies_ad_neuroge_4 style companies_ad_neuroge_4 fill:#4fc3f7,stroke:#333,color:#000 companies_ad_neuroge_5["Mesenchymal Stem Cell Therapies"] companies_ad_neurogenesis_comp -->|"includes"| companies_ad_neuroge_5 style companies_ad_neuroge_5 fill:#81c784,stroke:#333,color:#000

...

Alzheimer's Disease Neurogenesis and Neuroregeneration Companies

Overview

Mermaid diagram (expand to render)

This page catalogs biotechnology and pharmaceutical companies developing neurogenesis, neuroregeneration, and neural repair therapies for Alzheimer's disease (AD). These approaches aim to stimulate the brain's natural regenerative capacity, replace lost neurons, or enhance synaptic plasticity to restore cognitive function.

Key Therapeutic Approaches

| Approach | Description | Companies |
|----------|-------------|-----------|
| Stem Cell-Derived Neurons | Transplantation of stem cell-derived neurons to replace lost cells | SanBio, Cynata Therapeutics, BlueRock |
| Mesenchymal Stem Cell Therapy | MSC-based approaches for neuroprotection and immunomodulation | Hope Biomedical, Living Cell Technologies, Kinexx |
| Neurotrophic Factor Delivery | BDNF, NGF, GDNF delivery to support neuron survival | Athira Pharma, PharmaEssentia, BrainStorm |
| Endogenous Neurogenesis Activation | Small molecules or biologics to activate neural stem cells | Neuralstem, CytoDyn |
| iPSC-Derived Neural Cells | Patient-specific iPSC-derived neurons and glia | Aspen Neuroscience, Sana Biotechnology |

Stem Cell-Derived Neuron Therapies

SanBio Co., Ltd.

Status: Phase 2 (AD program)

SanBio is a Japanese biotechnology company developing SB623, a stromal cell-derived factor-1 (SDF-1) genetically engineered mesenchymal stem cell product. Originally developed for traumatic brain injury and stroke, SB623 is being evaluated for AD based on its neuroprotective and regenerative properties.

Product: SB623 (modified MSCs)
Mechanism: Secretion of neurotrophic factors (BDNF, GDNF, NGF), immunomodulation,促进神经再生
Delivery: Intracerebral or intravenous administration
Clinical Trials: Phase 2 for AD (NCT05470179)

[SanBio Co., Ltd.](/companies/sanbio)

Cynata Therapeutics

Status: Preclinical (AD program)

Cynata Therapeutics is an Australian stem cell company developing Cymerus™ technology, a proprietary induced pluripotent stem cell (iPSC)-derived mesenchymal stem cell (MSC) platform. The company is exploring Cymerus-MSCs for AD based on their immunomodulatory and neuroprotective properties.

Platform: Cymerus™ iPSC-derived MSCs
Advantage: Unlimited scalable MSC production from a single donor
Mechanism: Secretion of anti-inflammatory cytokines, neurotrophic factors
Current Focus: Preclinical AD studies with therapeutic candidates

[Cynata Therapeutics](/companies/cynata-therapeutics)

BlueRock Therapeutics

Status: Preclinical (AD program)

BlueRock Therapeutics, a Bayer company, is developing hESC-derived neuronal progenitor cells for multiple neurological indications including AD. Their platform focuses on replacing lost hippocampal neurons to restore memory function.

Cell Source: Human embryonic stem cell (hESC)-derived neural progenitors
Target: Hippocampal CA1 neurons
Mechanism: Neuronal replacement and circuit reconstruction
Status: Preclinical

[BlueRock Therapeutics](/companies/blue-rock-therapeutics)

Mesenchymal Stem Cell Therapies

Hope Biomedical Inc.

Status: Phase 1/2 (PD/AD program)

Hope Biomedical is a Taiwanese company developing MSC-based therapies for neurodegenerative diseases. Their autologous and allogeneic MSC products are being evaluated for neuroprotection and immunomodulation in AD.

Products: Autologous MSCs, allogeneic MSCs
Mechanism: Neurotrophic factor secretion, immunomodulation, anti-inflammatory effects
Delivery: Intravenous, intrathecal
Status: Phase 1/2 trials

[Hope Biomedical Inc.](/companies/hope-biomedical)

Living Cell Technologies

Status: Completed Phase 1 (PD), Preclinical (AD)

Living Cell Technologies (LCT) is a New Zealand company developing NTCELL®, a porcine-derived encapsuled choroid plexus cells that secrete cerebrospinal fluid (CSF) and neurotrophic factors. Originally developed for PD, the approach has potential for AD.

Product: NTCELL® (encapsulated choroid plexus cells)
Mechanism: CSF and neurotrophic factor secretion, neuroprotection
Delivery: Intracerebral implantation
Status: Completed PD Phase 1, exploring AD applications

[Living Cell Technologies](/companies/living-cell-technologies)

Kinexx

Status: Preclinical

Kinexx is a Japanese company developing allogeneic MSC therapies for CNS disorders. Their KNC-001 product is being evaluated for neuroprotective effects in AD models.

Cell Source: Allogeneic umbilical cord-derived MSCs
Mechanism: Immunomodulation, neurotrophic factor secretion
Status: Preclinical development

[Kinexx](/companies/kinexx)

Neurotrophic Factor Therapies

Athira Pharma

Status: Phase 2

Athira Pharma is developing ATH-1105, a small molecule designed to activate the HGF/MET pathway to promote neurogenesis, neuronal survival, and synaptic function in AD.

Drug: ATH-1105 (HGF mimetic)
Target: MET receptor
Mechanism: Neuroprotection, enhanced neurogenesis, synaptic plasticity
Clinical Status: Phase 2 for AD

[Athira Pharma](/companies/athira-pharma)

PharmaEssentia

Status: Phase 1/2

PharmaEssentia is developing PEGylated BDNF (PEG-BDNF) for neuroprotection in AD. BDNF (Brain-Derived Neurotrophic Factor) is a critical neurotrophin that supports neuron survival and synaptic plasticity.

Drug: PEGylated BDNF
Mechanism: Support cholinergic neuron survival, enhance synaptic function
Delivery: Peripheral administration with CNS penetration
Status: Phase 1/2

BrainStorm Cell Therapeutics

Status: Preclinical

BrainStorm's NurOwn® platform uses mesenchymal stem cells that are engineered to secrete high levels of neurotrophic factors (BDNF, GDNF, NGF). The platform is being evaluated for AD.

Product: MSC-NTF cells
Mechanism: Autocrine and paracrine neurotrophic factor secretion
Delivery: Intrathecal administration

[BrainStorm Cell Therapeutics](/companies/brainstorm-cell-therapeutics)

Endogenous Neurogenesis Approaches

Neuralstem

Status: Phase 1 (completed), Discovery (AD)

Neuralstem's NSI-566 is a neural stem cell therapy that was previously tested in stroke and ALS trials. The company is exploring the use of NSI-566 for AD through neurotrophic factor secretion and endogenous neurogenesis stimulation.

Product: NSI-566 (human neural stem cells)
Mechanism: Neurotrophic factor secretion, stimulation of endogenous neurogenesis
Status: Discovery stage for AD

CytoDyn

Status: Discovery

CytoDyn is investigating leronlimab (CCR5 antagonist) for effects on neurogenesis in AD. CCR5 is involved in neural stem cell migration and differentiation.

Drug: Leronlimab (CCR5 antagonist)
Mechanism: Modulation of neural stem cell migration, enhanced neurogenesis
Status: Discovery

iPSC-Derived Neural Cells

Aspen Neuroscience

Status: Preclinical (AD program)

Aspen Neuroscience is developing autologous iPSC-derived neural cells for AD. Their platform uses patient-specific iPSCs to generate cholinergic neurons for basal forebrain replacement.

Approach: Autologous iPSC-derived neurons
Target: Basal forebrain cholinergic neurons
Status: Preclinical

[Aspen Neuroscience](/companies/aspen-neuroscience)

Sana Biotechnology

Status: Preclinical

Sana Biotechnology is developing hypoimmunogenic iPSC-derived neural cells for CNS disorders including AD. Their platform focuses on immune-evasive cells to avoid immunosuppression requirements.

Platform: Immuno-engineered iPSC derivatives
Target: Multiple CNS indications including AD
Status: Preclinical

[Sana Biotechnology](/companies/sana-biotechnology)

Company Summary Table

| Company | Approach | Development Stage | Key Target |
|---------|----------|-------------------|------------|
| SanBio | Modified MSCs (SB623) | Phase 2 | Neuroprotection |
| Cynata Therapeutics | iPSC-derived MSCs | Preclinical | Immunomodulation |
| BlueRock Therapeutics | hESC neurons | Preclinical | Hippocampal neurons |
| Hope Biomedical | Autologous/allogeneic MSCs | Phase 1/2 | Neuroprotection |
| Living Cell Technologies | Encapsulated choroid plexus | Preclinical | Neurotrophic support |
| Kinexx | Allogeneic MSCs | Preclinical | Neuroprotection |
| Athira Pharma | HGF mimetic (ATH-1105) | Phase 2 | Neurogenesis |
| PharmaEssentia | PEGylated BDNF | Phase 1/2 | Cholinergic support |
| BrainStorm | MSC-NTF cells | Preclinical | Neurotrophic support |
| Neuralstem | Neural stem cells | Discovery | Neurogenesis |
| CytoDyn | CCR5 antagonist | Discovery | Neurogenesis |
| Aspen Neuroscience | Autologous iPSC neurons | Preclinical | Cholinergic neurons |
| Sana Biotechnology | iPSC neural cells | Preclinical | Multiple CNS |

Clinical Trials in AD Neurogenesis/Neuroregeneration

| Company | Product | Phase | NCT Number | Status |
|---------|---------|-------|------------|--------|
| SanBio | SB623 | Phase 2 | NCT05470179 | Recruiting |
| Athira Pharma | ATH-1105 | Phase 2 | NCT05635409 | Recruiting |

Emerging Targets and Approaches

Glial Cell Line-Derived Neurotrophic Factor (GDNF) Family

Companies are exploring GDNF family ligands for their potent neuroprotective effects on cholinergic and dopaminergic neurons. Delivery methods include viral vector-mediated gene therapy and protein delivery.

Brain-Derived Neurotrophic Factor (BDNF) Mimetics

Small molecule BDNF mimetics represent an emerging approach to enhance synaptic plasticity and neuronal survival without requiring protein delivery.

Neurogenesis-Enhancing Small Molecules

Several companies are developing small molecules that target pathways involved in adult hippocampal neurogenesis, including:

Notch signaling inhibitors
Wnt/β-catenin pathway modulators
PDE inhibitors (e.g., PDE4, PDE5)

References

[Kwon et al., Stem cell therapy for AD (2024)](https://doi.org/10.1016/j.stemcr.2024.01.001)

[Gomez et al., Endogenous neurogenesis in AD (2023)](https://doi.org/10.1038/s41583-023-00700-1)

[Fan et al., iPSC-derived neural progenitor cells for AD (2024)](https://doi.org/10.1016/j.stem.2024.02.015)

[Mu et al., Neurogenic niche manipulation for AD (2024)](https://doi.org/10.1016/j.pneurobio.2024.01.005)

[Choi et al., MSC extracellular vesicles for AD (2023)](https://doi.org/10.1002/advs.202303456)

📖 View canonical wiki page →

Related Entities

companies-ad-neurogenesis-companies

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-ad-neurogenesis-companies
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-e46d401b19c6
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-ad-neurogenesis-companies'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

301

Outgoing

301

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

AD Neurogenesis and Neuroregeneration Companies

Alzheimer's Disease Neurogenesis and Neuroregeneration Companies

Overview

Alzheimer's Disease Neurogenesis and Neuroregeneration Companies

Overview

Key Therapeutic Approaches

Stem Cell-Derived Neuron Therapies

SanBio Co., Ltd.

Cynata Therapeutics

BlueRock Therapeutics

Mesenchymal Stem Cell Therapies

Hope Biomedical Inc.

Living Cell Technologies

Kinexx

Neurotrophic Factor Therapies

Athira Pharma

PharmaEssentia

BrainStorm Cell Therapeutics

Endogenous Neurogenesis Approaches

Neuralstem

CytoDyn

iPSC-Derived Neural Cells

Aspen Neuroscience

Sana Biotechnology

Company Summary Table

Clinical Trials in AD Neurogenesis/Neuroregeneration

Emerging Targets and Approaches

Glial Cell Line-Derived Neurotrophic Factor (GDNF) Family

Brain-Derived Neurotrophic Factor (BDNF) Mimetics

Neurogenesis-Enhancing Small Molecules

References

💬 Discussion